MyFinsight
Home
Blog
About
Proceeds from offering,
net of costs
$1,860,000
Net cash provided by
financing activities
$1,454,047
Canceled cashflow
$405,953
Net change in cash
-$840,875
(55.54%↑ Y/Y)
Canceled cashflow
$1,454,047
Stock-based compensation
$490,997
(-44.45%↓ Y/Y)
Accounts payable and
accrued expenses
$443,607
(149.95%↑ Y/Y)
Amortization of prepaid
contracts
$191,142
(-49.72%↓ Y/Y)
Inventory
-$12,778
Change in operating
lease right of use...
$3,842
Other assets
-$3,687
Deferred revenue
$859
Refund liability
$477
Payment on convertible
note payable
$405,953
Net cash used in
operating activities
-$2,294,922
(-21.34%↓ Y/Y)
Canceled cashflow
$1,147,389
Net loss
-$2,274,397
(39.86%↑ Y/Y)
Pharmala escrow deposit
-other assets
$600,000
Gain on change in fair
value of convertible...
$549,098
Accounts receivable
$10,241
Accrued compensation
-$8,575
(-101.94%↓ Y/Y)
Back
Back
Cash Flow
JUPITER NEUROSCIENCES, INC. (JUNS)
JUPITER NEUROSCIENCES, INC. (JUNS)
source: myfinsight.com